1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2023

  • April 2015
  • 377 pages
  • GlobalData
Report ID: 3091019

Summary

Table of Contents

Search Inside

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2023

Summary

Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for melanoma are categorized into immunotherapies and BRAF mutation-targeted therapies. GlobalData estimates the 2013 sales for melanoma at approximately $1.34 billion across the 8MM covered in this report. The market will increase by four-fold over the forecast period, reaching $5.64 billion in 2023 at a CAGR of 15.5%. This growth will be driven by an increase in melanoma incident cases as well as the approval and uptake of premium-priced products, such as PD-1-targeting mAbs and BRAF/MEK inhibitor combinations. GlobalData expects, by the end of the forecast period, the checkpoint immunotherapy drug class to dominate the melanoma market (including both BRAF wild-type and mutation-positive patient segments) with an overall 67% share of the melanoma market.

The melanoma pipeline is strong; however, GlobalData expects none of these drugs to have a major impact on the overall melanoma market, as the market is crowded with effective immunotherapies and BRAF mutation-targeted agents. The challenge for new entrants into the melanoma market is to find patient populations that are currently underserved. One of the opportunities for the companies is to work cooperatively to develop novel combinations of immuno/targeted-therapies.

Highlights

Key Questions Answered

- The melanoma space is filled with the excitement of recently approved anti-PD-1 immunotherapies, which are expected to revolutionize the treatment landscape. What will be the impact of these newly approved drugs and their projected label expansions on the melanoma sales?
- As the melanoma market is getting increasingly crowded with multiple anti-PD-1 immunotherapies and BRAF mutation-targeted agents, opportunities for new entrants become limited. What R&D strategies are being used by drug makers to remain competitive?
- The survival of patients with metastatic melanoma remains short, especially for those who do not response to anti-PD-1 immunotherapies. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the melanoma market?

Key Findings

- One of the main drivers of the enormous expansion of the gout market will be the launch of premium-priced metastatic therapies, such as anti-PD-1 immunotherapy and BRAF/MEK inhibitor combinations. These drugs will extend treatment duration and replace cheaper, generic, chemotherapy regimens.
- Another strong driver will be the label extension of current therapies into the new settings; for example, PD-1s will garner label extension for the first-line treatment in 2015-16, and the metastatic brands are expected to be approved in the adjuvant setting in the second half of the forecast period.
- Companies are focusing on the development of combination immunotherapies, trying to improve the response rate and response duration of drugs.
- One of the largest unmet needs is a need for efficacious treatment options for BRAF wild-type patients. Approximately half of melanoma patients do not have BRAF mutations, and are therefore non-eligible for BRAF/MEK inhibitor treatments. Other unmet needs include therapies for PD-1 immunotherapy non-responders, adjuvant treatment for patients with resected melanoma, effective treatment for brain metastasis, and predictive markers for therapeutic response to immunotherapies.

Scope

- Overview of melanoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized melanoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in six patient segments (including adjuvant, BRAF mutated and BRAF wild-type), forecast from 2013 to 2023.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the melanoma therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.
- Analysis of the current and future market competition in the global melanoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global melanoma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Ulcerative Colitis Market and Forecast Analysis

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Ulcerative colitis is a chronic inflammatory bowel disease that is characterized by inappropriate diffuse inflammation of the rectal and colonic mucosa, which occurs in the innermost laye ...

Crohn’s Disease Market and Forecast Analysis

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Crohn’s disease involves inflammation of the gastrointestinal (GI) tract and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of ...

OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • February 2017
  • by GlobalData

OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025 Summary Immune Thrombocytopenia (ITP) is an autoimmune-related bleeding disorder characterized by a low platelet ...

Nash: Kol Insight [2017]

June 2017 $ 9015

Hnscc: Kol Insight - 2017

March 2017 $ 8355

Car-t Disease Outlook [2017]

June 2017 $ 8355

Download Unlimited Documents from Trusted Public Sources

Vaccine Market and Influenza Statistics in India

  • June 2017
    6 pages
  • Vaccine  

    Influenza  

    Diabetes  

  • India  

    United States  

View report >

Hormone and Therapy Market in Pakistan and the US

  • June 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Respiratory Treatment and Therapy Market in the US

  • June 2017
    14 pages
  • Respiratory Tre...  

    Therapy  

  • United States  

View report >

Therapy Market

4 days ago

Diabetes Statistics

4 days ago

Related Market Segments :

Therapy
Targeted Therapy

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.